Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6971664 | 1.00 | SLC18A3 (0.49) | SLC18A3MEN1KMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL6498838 | 0.98 | SLC18A3 (0.48) | SLC18A3MEN1KMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL7421281 | 0.98 | SLC18A3 (0.48) | SLC18A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL28024374 | 0.93 | CXCR4 (0.49) | SLC18A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7422727 | 0.90 | MEN1 (0.51) | SLC18A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL9061088 | 0.89 | SLC18A3 (0.43) | SLC18A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL21750427 | 0.89 | HRH2 (0.46) | SLC18A3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL20609092 | 0.86 | SLC18A3 (0.56) | SLC18A3MEN1KMT2AALDH1A1CHRM5 | |
| SCHEMBL9328257 | 0.86 | — | — | |
| SCHEMBL9423512 | 0.84 | MEN1 (0.46) | MEN1KMT2AALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997045422-A1 | ANTI-NEURODEGENERATIVELY EFFECTIVE 10-AMINOALIPHATYL-DIBENZ[b,f]OXEPINE SALTS | NOVARTIS AG (CH) | 1997-12-04 | — | — | WO | claimed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023093845-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-5270312-A | Substituted piperazines as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0556332-A1 | SUBSTITUTED TETRAHYDROPYRIDINES AND HYDROXYPIPERIDINES AS CENTRAL NERVOUS SYSTEM AGENTS. | WARNER LAMBERT CO (US) | 1993-08-25 | — | — | EP | disclosed |
| EP-0556329-A1 | SUBSTITUTED PIPERAZINES AS CENTRAL NERVOUS SYSTEM AGENTS. | WARNER LAMBERT CO (US) | 1993-08-25 | — | — | EP | disclosed |
| WO-1992007832-A2 | SUBSTITUTED PIPERAZINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992007831-A1 | SUBSTITUTED TETRAHYDROPYRIDINES AND HYDROXYPIPERIDINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-05-14 | — | — | WO | disclosed |
| US-4243805-A | 3 Fluoro-10-piperazino-8-substituted 10,11-dihydrodibenzo-(bf) thiepins and method for the preparation thereof | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1981-01-06 | — | — | US | disclosed |
| US-4035385-A | NEUROLEPTIC AGENTS, PROPYNYLAMINE-SUBSTITUTED | HOFFMANN-LA ROCHE INC. (US) | 1977-07-12 | — | — | US | disclosed |
| US-4035386-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-07-12 | — | — | US | disclosed |
| US-4028348-A | 6-Amino-5β,19-cycloandrostane derivatives | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1977-06-07 | — | — | US | disclosed |
| US-4005105-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SLC18A3 4800/4885MEN1 348/4885KMT2A 2081/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | SLC18A3 2416/4885MEN1 4071/4885KMT2A 3556/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | SLC18A3 2416/4885MEN1 4071/4885KMT2A 3556/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | SLC18A3 2326/4885MEN1 3345/4885KMT2A 3260/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SLC18A3 4800/4885MEN1 348/4885KMT2A 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.